含培门冬酶注射液的VDPAP方案诱导治疗儿童急性淋巴细胞白血病的临床价值研究  

Study the Clinical Efficacy of Thalidomide Combined with Chemotherapy in the Treatment of Acute Leukemia

作　　者：秦凡 常占国[1] Qin Fan;Chang Zhanguo(Department of Oncology and Hematology,Nanyang First people's Hospital,Nanyang 473000,China)

机构地区：[1]南阳市第一人民医院肿瘤血液内科,河南南阳473000

出　　处：《哈尔滨医药》2020年第2期116-117,共2页Harbin Medical Journal

摘　　要：目的研究儿童急性淋巴细胞白血病中采用含培门冬酶注射液的VDPAP方案诱导的效果。方法选取我院收治的急性淋巴细胞白血病的儿童患者90例为研究对象,采用左旋门冬酰胺酶治疗的患儿作为对照组(45例),采用培门冬酶治疗的患儿作为观察组(45例),比较两组经过治疗后的临床效果和不良反应。结果观察组急性淋巴细胞白血病患儿的总有效率(97.78%)明显高于对照组急性淋巴细胞白血病患儿的总有效率(71.11%);观察组急性淋巴细胞白血病患儿的不良反应发生率(6.67%)明显低于对照组急性淋巴细胞白血病患儿的不良反应发生率(37.78%),差异有统计学意义(P<0.05)。结论采用培门冬酶注射液的VDPAP方案治疗急性淋巴细胞白血病的临床效果较为明显,安全性高。Objective To study the clinical efficacy of chemotherapy combined with thalidomide in the treatment of acute leukemia.Methods 80 patients with acute leukemia admitted to our hospital from August 2017 to August 2018 were divided into control group(routine chemotherapy treatment)and observation group(chemotherapy combined with thalidomide treatment),40 cases in each group.The basic fibroblast growth factor(bFGF),vascular endothelial growth factor(VEGF)and clinical efficacy of the patients after treatment were compared.Results The bFGF(2.18+0.30)ng/mL and the VEGF(214.65+11.30)pg/mL of the observation group were significantly lower than those of the control group(2.40+0.40)ng/mL and the VEGF(294.23+10.50)pg/mL;the total effective rate of the observation group(85.00%)was significantly higher than that of the control group(62.50%)and the difference was statistically significant(P<0.05).Conclusion Chemotherapy combined with thalidomide is effective in the treatment of acute leukemia,and can effectively reduce the levels of bFGF and VEGF.

关 键 词：含培门冬酶 VDPAP方案 儿童 急性淋巴细胞白血病 

分 类 号：R729[医药卫生—儿科]